CEA cell adhesion molecule pseudogene 5Genealiases: CEACAM26P · CGM12
Q-omics provides the consensus-scored CEACAMP5 profile across patient tissues and cancer cell-line models. CEACAMP5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CEACAMP5 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, CEACAMP5 RNA expression shows 14,091 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KIRP, and ACC as cancer lineages where CEACAMP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP5 survival associations across molecular data types. CEACAMP5 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP5 RNA expression–survival associations across cancer types. High CEACAMP5 expression shows unfavorable associations in THCA and ACC, but favorable associations in UVM, LUSC, BLCA and LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CEACAMP5 RNA expression.
This table summarizes CEACAMP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP5 shows lower tumor expression in BRCA, KIRC, UCEC and STAD and higher tumor expression in KIRP and LUAD. The KIRP box plot shows higher CEACAMP5 RNA expression in tumor versus normal tissue (log2 FC = +0.522, t-test p = .009).
This table shows molecular features associated with CEACAMP5 in patient tissues and cancer cell lines. In patient samples, CEACAMP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
